Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 57

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Sjogren's syndrome

Not yet recruiting

A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren's syndrome.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud University Medical Center

Haemophagocytic lymphohistiocytosis

Not yet recruiting

Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dermatitis atopic

Not yet recruiting

A Study of Lebrikizumab for Adults and Adolescents with Moderate to Severe Atopic Dermatitis to Evaluate Effects on Eczema and Skin Barrier Function

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Lebrikizumab
  • Sponsor:Region Oestergoetland

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Inflammation

Not yet recruiting

Testing acetylsalicylic acid and ketorolac to reduce complications after cancer surgery in patients with high inflammation levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Cholangitis sclerosing

Not yet recruiting

Study of Fecal Microbiota Transplantation Compared to Sham Treatment for Patients with Primary Sclerosing Cholangitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Endocrine ophthalmopathy+1

Not yet recruiting

A study to test if atorvastatin can prevent eye disease in patients newly diagnosed with Graves' disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Skane

Type 1 diabetes mellitus+1

Not yet recruiting

A study testing dapagliflozin and SC0062 together compared to SC0062 alone in adults with type 1 diabetes and chronic kidney disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Systemic scleroderma

Not yet recruiting

Comparing Dapagliflozin and Tocilizumab for Treating Patients with Systemic Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Centrum Medycznego Ksztalcenia Podyplomowego

Cardiac sarcoidosis

Not yet recruiting

A Study Testing the Accuracy of 68Ga-Pentixafor PET/CT Imaging in Patients with Cardiac Sarcoidosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga)
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Mite allergy

Not yet recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.